Nalbuphine Versus Ketorolac as an Adjuvant to Local Wound Infiltration Anesthesia in Open Colorectal Surgery: A Prospective Randomized Controlled Study

Abstract

Introduction

Adding adjuvants to local wound infiltration (LWI) provides long analgesic duration with fewer adverse effects. We aimed to compare the clinical effects of nalbuphine and ketorolac as an adjuvant to LWI in patients undergoing open colorectal cancer surgery.

Method

A total of 126 ASA I–III patients aged ≥ 18 years who were scheduled for open colorectal cancer surgery were included. Patients were randomly assigned to receive LWI using 10 mL 0.75% ropivacaine, with 20 mL normal saline (group R), 10 mg nalbuphine in 1 mL (group RN), or 25 mg ketorolac in 0.8 mL (group RK). Analgesia duration was the primary outcome. The total 48-h postoperative morphine-equivalent consumption and additional rescue analgesia rates were recorded as key secondary outcomes.

Results

Among 126 patients randomized, 124 completed the trial. The duration until the first press of the analgesia pump was significantly shorter in group R (median: 320.0 min) compared with group RN (median: 829.5 min) and group RK (median: 820.0 min) (P < 0.001). The median difference in morphine consumption was 113.0 mg for group R vs. group RN (P < 0.001), and 115.5 mg for group R vs. group RK (P < 0.001). The proportion of patients using additional morphine within the first day after surgery in group R showed a higher relative risk (RR) compared with group RN (RR, 3.89; P = 0.001) and group RK (RR, 3.17; P = 0.001). There were no apparent differences between the RN and RK groups in any outcomes, whether in adjusted or unadjusted analysis.

Conclusions

Among patients undergoing open colorectal cancer surgery, both nalbuphine and ketorolac infiltration achieved equally prolonged duration of analgesia and reduced morphine consumption compared with ropivacaine alone after surgery, suggesting that the equivalent analgesic dose of nalbuphine and ketorolac as local anesthetic adjuvants in LWI could have a similar analgesic effect.

Trial Registration

ChiCTR1800019209.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40122-021-00246-z.

Key Summary Points

Why carry out this study?

Adding adjuvants to local wound infiltration (LWI) provides long analgesic duration with fewer adverse effects. However, there is no high-quality evidence for comparison of the clinical effects of nalbuphine and ketorolac as an adjuvant to LWI in patients undergoing open colorectal cancer surgery.

We hypothesized that both nalbuphine and ketorolac as an adjuvant for LWI would contribute to more outstanding results in prolonging postoperative analgesia and relieving acute pain than ropivacaine alone, and that ketorolac would be more effective in reducing acute postoperative pain than nalbuphine.

What was learned from the study?

The results showed that both nalbuphine and ketorolac infiltration prolonged the duration of analgesia and reduced morphine consumption compared with ropivacaine alone after open colorectal surgery.

The results of the present study suggest that ketorolac infiltration did not result in a clinically important improvement over nalbuphine infiltration.

Generally, the infiltration of these agents (nalbuphine and ketorolac) appears to be safe, but the results should be interpreted with caution as exploratory outcomes.

Digital Features

This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.13913348.

Introduction

Local wound infiltration (LWI), where the local anesthetic and/or other drugs are injected directly at the incision point, is a simple and effective analgesic procedure for large incision in abdominal surgery [1–3]. However, like nerve block, the insufficient analgesia time caused by local anesthetics used on their own is a major limitation of LWI [3, 4]. Improvement in perioperative pain is more valuable than immediate postoperative pain relief [5, 6]. To address these issues, opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), dexmedetomidine, dexamethasone, ketamine, and magnesium are often used as adjuvants to local anesthetics to prolong the duration and enhance LWI efficacy [3, 7, 8].

Opioids and NSAIDs are the two most essential analgesics. The analgesic effects of both opioids (nalbuphine) [9–11] and NSAIDs (ketorolac) [12–14] as local anesthetic adjuvants in various nerve blocks are well established compared with placebo. With regard to LWI, there is high-quality evidence that ketorolac 30–60 mg may be an effective infiltration agent, with peripheral analgesia beyond the effects of systemic absorption [3, 15, 16]. However, high-quality randomized controlled trials should be conducted to confirm the results, as studies to date are of mixed quality [3]. On the other hand, it should be noted that while previous research indicated that nalbuphine provided longer and more effective postoperative analgesia as an adjuvant in intraspinal and nerve block, no study has confirmed the clinical effect of nalbuphine on LWI. To the best of our knowledge, there is no high-quality evidence for comparison of nalbuphine and ketorolac in LWI.

The safety of adjuvants, including nalbuphine and ketorolac, is largely unknown in the perioperative period. The rate of LWI-related adverse effects, such as drug infiltration complications, delayed wound healing, infection and pruritus, remains undefined, and it is critical that LWI not exacerbate these events. Although adjuvants have been associated with adverse outcomes in some settings, this association has not been fully investigated in LWI [3].

This trial investigating LWI with nalbuphine and ketorolac (LWINK) aimed to compare nalbuphine and ketorolac as an adjuvant to 0.25% ropivacaine for LWI anesthesia in patients undergoing open colorectal surgery. The hypotheses were as follows: (1) Both nalbuphine and ketorolac as an adjuvant for LWI would contribute to more outstanding results in prolonging postoperative analgesia and relieving acute pain compared with ropivacaine alone. (2) Ketorolac would be more effective in reducing acute postoperative pain than nalbuphine. (3) Neither nalbuphine nor ketorolac would increase the risk of LWI-related adverse effects.

Methods

Trial Design and Participants

Before patient enrollment, the trial was approved by the Ethical Committee of Henan University (registration no. 2018LW012) on October 20, 2018. The trial was conducted in accordance with the Declaration of Helsinki and registered at the Chinese Clinical Trial Registry (registration no. ChiCTR1800019209, chictr.org.cn). The actual research start date was November 15, 2018, and the main actual completion date was December 31, 2019. A data and safety monitoring board (DSMB) was established to oversee the safety of the study and check the integrity of data.

This LWINK trial was a single-center, prospective, randomized, double-blind study. Patients with American Society of Anesthesiologists (ASA) physical status classes I–III, aged 28–80 years and scheduled for open colorectal surgery were considered eligible to participate in the study after providing written informed consent. Major exclusion criteria included allergy to the study drugs (local anesthetics, opioids and NSAIDs); chronic pain treatment or chronic steroid therapy [17]; psychiatric disorders; neuromuscular or endocrine diseases; diabetes mellitus; coagulopathy; cardiac, liver or renal diseases; and pregnant and lactating women. Those who underwent laparoscopic surgery, were sent to the intensive care unit after the operation, presented severe postoperative infection, or refused to participate in the study were also excluded from the study.

Randomization and Blinding

A computer-generated simple randomization list was used to classify the patients into three groups at a 1:1:1 ratio using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp. Armonk, NY, USA). The three groups were as follows: group R (n = 41): 10 mL of ropivacaine 0.75% + 20 mL normal saline; group RN (n = 42): 10 mL of ropivacaine 0.75% + 19 mL normal saline + subcutaneous injection of nalbuphine (10 mg) in 1 mL; and group RK (n = 41): 10 mL of ropivacaine 0.75% + 19.2 mL normal saline + subcutaneous ketorolac (25 mg) in 0.8 mL.

Intravenous nalbuphine or ketorolac was not administered to all patients perioperatively. Before the operation, an anesthesiologist, blind to the groups, evaluated the preoperative status of the patients to determine whether they met the inclusion criteria of the study. All patients were taught how to use patient-controlled intravenous analgesia (PCIA) and the numerical rating scale (NRS, with 0: no pain, to 10: the worst imaginable pain). The randomization numbers were stored in a locked container in the operating room. A nurse who did not participate in the trial opened the appropriate numbered envelope and prepared the drugs. The syringe cylinder was covered using the same opaque material for uniformity. Incision length was measured before skin closure, and the group of surgeons who were not involved in the study performed the LWI.

Anesthesia Procedure

All patients were instructed to fast for 8 h and refrain from intake of water for 4 h. In the operating room, peripheral venous access was established, and an infusion of a lactated Ringer’s solution was initiated. Five-lead electrocardiogram (ECG), heart rate (HR), noninvasive blood pressure (BP), respiratory rate (RR), and pulse oxygen saturation (SpO₂) were continuously monitored. Radial artery catheterization was performed to measure mean arterial pressure (MAP). Catheterization was conducted via the right internal jugular vein or right subclavian vein to monitor central venous pressure (CVP).

General anesthesia was induced with 0.5 μg/kg of sufentanil, 0.15–0.30 mg/kg of etomidate, and 0.2 mg/kg of cisatracurium. Etomidate, sevoflurane, remifentanil and cisatracurium were used to maintain the bispectral index (BIS) at 40–60, thereby maintaining anesthesia. After the operation, all patients were connected to the prepared PCIA pump and sent to the post-anesthesia care unit (PACU) for further observation.

Pain Management

Standardized analgesia was used in patients as follows: (1) The drug was infiltrated into the tissues around the entire incision, including the muscles and subcutaneous tissue, with 1 mL of drug per 1 cm incision. (2) For postoperative analgesia, all patients received PCIA. PCIA was administered for NRS ≥ 4 or upon patient request. The analgesic pump configuration was as follows: 2.0 μg/ kg sufentanil diluted to 100 mL (0.5 mL bolus, a lockout time interval of 15 min and 1 h of 2 mL without any baseline infusion). (3) During early recovery in the PACU, rescue intramuscular morphine was given as needed when NRS was ≥ 4; tropisetron 5 mg was injected intravenously when nausea and vomiting occurred. (4) In the ward, additional rescue analgesia measures (intravenous morphine 5 mg) were taken whenever the PCIA analgesic effect was still unsatisfactory.

Trial Outcomes

The primary outcome was analgesia duration, defined as the time in minutes to the first press of the analgesia pump. The total morphine-equivalent consumption over the 48-h postoperative period and the additional rescue analgesia rates for the three groups were recorded within 2 days after surgery as key secondary outcomes. The total morphine-equivalent consumption included both sufentanil dose in the PCIA pump and rescue morphine dose. We employed a published equivalence formula, cumulative opioid consumption with opioid drugs other than morphine converted to morphine-equivalent doses, where 10 mg intravenous (i.v.) morphine = 0.01 mg i.v. sufentanil. Other secondary outcomes were NRS (score range, 0 [no pain] to 10 [worst imaginable pain]) scores on resting and moving (taking a deep breath) at 2, 4, 8, 12, 24, 48, and 72 h postoperatively. Adverse events (nausea, vomiting, local anesthetic toxicity, hypotension, bradycardia, gastrointestinal bleeding, pruritus and wound infection) from 0 to 48 h were also recorded as exploratory outcomes.

Sample Size

We conducted a preliminary study of 15 patients (five per group) and calculated the sample size according to the primary outcome. The calculation of sample size and power of the test were performed using PASS software version 15 (NCSS, Kaysville, UT, USA). One-way analysis of variance (ANOVA) was selected and grouped into three groups; the group allocation ratio was 1:1:1, with hypothesized means of 381.3, 607.5 and 620.9 and SD of 107.5, 133.1, and 142.7, respectively. The required sample size for each group was calculated to be 36 at a power (1 − β) of 0.90, and a Bonferroni-corrected alpha error of 0.01 [17]. It was estimated to be at least 40 per group considering 10% dropouts and incomplete follow-up.

Statistical Analysis

Statistical analysis was performed by an independent statistician (CGN) with IBM SPSS v25.0 and R software (Version 3.5.3, R Foundation for Statistical Computing). The modified intention-to-treat data were used for analysis with no planned interim analysis. We did not address the missing data because the data for postoperative assessments were less than 5%. All reported P values are two-tailed.

All data were checked for normal distribution with the Kolmogorov–Smirnov test. Continuous data are presented as mean with a confidence interval (CI) or standard deviation (SD) for normally distributed variables and medians with CI for non-normally distributed data. Categorical variables are summarized using numbers (proportions) or proportions with CI.

The main analysis of the primary outcome of duration of analgesia employed pairwise comparisons between groups using the Kruskal–Wallis test followed by Dunn-Bonferroni post hoc comparison for non-normally distributed data. Changes between groups are presented as median differences and CIs. The threshold for type I errors was adjusted to 0.05/3 = 0.017 for the pairwise comparisons between the three groups (three comparisons) for the primary outcome of analgesia duration [18]. For time-to-event outcomes (duration of analgesia), we analyzed the data using the Kaplan–Meier survival method and compared the groups using the log-rank test, with adjustment for multiple comparisons to ensure the reliability of results [17].

Generalized estimating equations (GEE) with robust standard error estimates were used to account for repeated measures of NRS data [18, 19]. The level of significance and corresponding CI were 0.001 and 99.9% for other secondary outcomes of NRS scores. Because all patients reported pain, sensitivity analyses were not performed to evaluate the statistical nature of the missing data (NRS = 0 was considered as missing data) [20].

Categorical data (rescue analgesia rates and the incidence of side effects) were analyzed using the Pearson χ² test or Fisher exact test, as appropriate. P < 0.017 (Bonferroni adjusted) was considered statistically significant for comparisons of rescue analgesia rates between groups, and the differences between groups were calculated using relative risk (RR) with 98.3% CI using the mean difference. The level of significance and corresponding confidence interval were set at 0.05 and 95% for the incidence of side effects [18].

Additionally, secondary analyses included adjusted analyses (for sex, age, wound length, and type of surgery) for the primary outcome and the key secondary outcomes. The adjusted analyses were tested for interaction with three groups by the GEE approach using the gee package in R software [18]. The results of the secondary analysis were interpreted as exploratory only.

Results

Patient Characteristics

A total of 153 participants were enrolled in this trial. However, 27 patients were disqualified for failing to meet the inclusion criteria or refusing to participate. Following randomization, no patients were canceled because of nonadherence to the protocol; thus, the remaining 126 patients were assigned to one of three groups, and 124 patients completed the study (Fig. 1). The patient characteristics (demographic, surgical and intraoperative medication use) were comparable between the three groups (Table 1).

Fig. 1.

Participant flow of the progress through the phases of the trial. R ropivacaine, RN ropivacaine + nalbuphine, RK ropivacaine + ketorolac

Table 1.

Demographic data and surgical characteristics

	Group R (n = 41)	Group RN (n = 42)	Group RK (n = 41)
Gender
Male	19 (46)	19 (45)	20 (49)
Female	22 (54)	23 (55)	21 (51)
Age, mean (SD), years	65.1 (11.0)	66.5 (9.5)	66.8 (9.9)
Height, mean (SD), cm	171.1 (4.3)	169.9 (5.2)	170.3 (5.3)
Weight, mean (SD), kg	65.2 (4.5)	64.7 (4.7)	65.5 (5.1)
ASA score
1. Healthy	20 (49)	18 (43)	19 (46)
2. Mild systemic disease	15 (36)	16 (38)	17 (42)
3. Severe systemic disease	6 (15)	8 (19)	5 (12)
Surgery
Right hemicolectomy	12 (29)	14 (33)	13 (32)
Left hemicolectomy	14 (34)	15 (36)	12 (29)
Sigmoidectomy	10 (25)	9 (21)	11 (27)
Anterior resection	2 (5)	2 (5)	3 (7)
Panproctocolectomy	3 (7)	2 (5)	2 (5)
Intraoperative medication use
Sufentanil, mean (range) (μg)	32.6 (29.0–37.5)	32.4 (28.0–37.5)	32.8 (28.5–38.5)
Sevoflurane, mean (range) (mL)	25.8 (19.5–34.6)	25.4 (19.1–33.7)	25.5 (18.9–34.1)
Remifentanil, mean (range) (mg)	3.3 (1.6–4.9)	3.1 (2.0–5.1)	2.9 (1.9–5.3)
Tropisetron	19 (46)	20 (48)	20 (49)
Duration of surgery, mean (SD) (min)	157.9 (16.5)	158.7 (15.8)	159.0 (15.5)
Wound length, mean (SD) (cm)	19.65 (1.0)	20.2 (1.1)	19.6 (0.9)

ASA American Society of Anesthesiologists, SD standard deviation, R ropivacaine, RN ropivacaine + nalbuphine, RK: ropivacaine + ketorolac

Data are reported as numbers (%) unless otherwise indicated

Primary Outcome

The median duration of analgesia in group R was 320.0 min (98.3% CI 308.5–332.0), and was 829.5 min (98.3% CI, 780.0 to 860.0) in group RN and 820.0 min (98.3% CI 812.0–877.0) in group RK. In the pairwise comparisons, the median difference was 492.0 min (98.3% CI 459.0–526.8; P < 0.001) between group R and group RN, and 513.0 min (98.3% CI 489.4–539.2; P < 0.001) between groups R and RK. However, there was no significant difference between group RN and group RK (19.5 min [98.3% CI −49.1 to 11.2]; P = 0.83) (Table 2).

Table 2.

Between-group comparisons of duration of analgesia

	Group R	Group RN	Group RK
Duration of analgesia, median (98.3% CI) (min)	320.0 (308.5–332.0)	829.5 (780.0–860.0)	820.0 (812.0–877.0)
Difference
Compared with group R (median) (98.3% CI), mina	NA	–492.0 (–526.8 to –459.0)	–513.0 (–539.2 to –489.4)
P valueb		P < 0.001	P < 0.001
Compared with group RN, median (98.3% CI) (min)a	NA	NA	–19.5 (–49.1 to 11.2)
P valueb			P = 0.83
Compared with group RK, median (98.3% CI) (min)a	NA	NA	NA
P valueb

NA not applicable, CI confidence interval, R ropivacaine, RN ropivacaine + nalbuphine, RK ropivacaine + ketorolac

^aConfidence intervals were calculated by Hodges-Lehmann estimation to estimate the median difference

^bP values were calculated using Kruskal–Wallis test

The Kaplan–Meier survival analysis of the time to the first press of the analgesia pump is shown in Fig. 2. The results of log-rank tests were consistent with the Kruskal–Wallis test. Secondary analyses revealed a similar result as in the main unadjusted analysis (see Table S1 in the electronic supplementary material for details).

Fig. 2.

Kaplan–Meier analysis for the first analgesic request in the three groups. R ropivacaine, RN ropivacaine + nalbuphine, RK ropivacaine + ketorolac

Key Secondary Outcomes

The total 48-h postoperative morphine-equivalent consumption in group R was 211.0 mg (98.3% CI 209.5–216.0), and it was 99.3 mg (98.3% CI 97.0–101.3) in group RN and 96.6 mg (98.3% CI 94.5–99.0) in group RK. Patients in group RN (median difference, 113.0 mg; 98.3% CI 109.5–116.0; P < 0.001) and group RK (median difference, 115.5 mg; 98.3% CI 112.0–119.0; P < 0.001) experienced lower 48-h postoperative total morphine-equivalent consumption compared with group R. There was no significant difference between group RN and group RK (2.6 mg [98.3% CI 0.0–5.4]; P = 0.022) (Table 3).

Table 3.

Key secondary outcomes

	Group R	Group RN	Group RK
48-h Total morphine equivalent administered, median (98.3% CI) (mg)a, b	211.0 (209.5–216.0)	99.3 (97.0–101.3)	96.6 (94.5–99.0)
Difference, median (98.3% CI) (mg)
Compared with group R	NA	113.0 (109.5–116.0)	115.5 (112.0–119.0)
P value		P < 0.001	P < 0.001
Compared with group RN	NA	NA	2.6 (0.0–5.4)
P value			P = 0.022c
Compared with group RK	NA	NA	NA
P value
Additional rescue analgesia rates within 2 days post-surgery
POD-1 (98.3% CI) (%)d	46.3 (27.8–65.7)	11.9 (3.0–28.8)	14.6 (4.4–32.4)
Absolute difference (RR) [98.3% CI] (%)
Compared with group R	NA	34.4 (3.89) [12.4–56.5]	31.7 (3.17) [8.9–54.5]
P value		P = 0.001	P = 0.002
Compared with group RN	NA	NA	–2.7 (0.81) [–20.5 to 15.0]
P value			P = 0.72
Compared with group RK	NA	NA	NA
P value
POD-2 (98.3% CI) (%)d	17.1 (5.8 to 35.3)	9.5 (1.9–25.7)	7.3 (1.0–22.9)
Absolute difference (RR) [98.3% CI] (%)
Compared with group R	NA	7.6 (1.79) [–10.2 to 25.3]	9.8 (2.33) [–7.3 to 26.8]
P value		P = 0.31e	P = 0.18e
Compared with group RN	NA	NA	2.2 (1.30) [–12.3 to 16.7]
P value			P = 0.72e
Compared with group RK	NA	NA	NA
P value

NA not applicable, CI confidence interval, RR relative risk, POD postoperative day; R ropivacaine, RN ropivacaine + nalbuphine, RK ropivacaine + ketorolac

^aTotal morphine equivalent is calculated as the sum of (sufentanil dose [μg] × 1) + morphine dose

^bConfidence intervals were calculated by the Hodges-Lehmann estimator to determine the median difference. P values were calculated using Kruskal–Wallis test

^cThis P value = 0.022 is above the prespecified threshold (level of significance) of P = 0.017

^dThe 98.3% confidence intervals for proportions were calculated using Clopper–Pearson method with binom.test

^eFisher's exact test

The proportion of additional rescue analgesia rates within the first day after surgery in group R was 46.3% (98.3% CI 27.8–65.7), and it was 11.9% (98.3% CI 3.0–28.8) in group RN and 14.6% (98.3% CI 4.4–32.4) in group RK. In a post hoc analysis, group R showed a higher RR for patients using additional morphine compared with group RN (RR, 3.89 [98.3% CI 12.4–56.5]; P = 0.001) and group RK (RR, 3.17 [98.3% CI 8.9–54.5]; P = 0.001). There was no significant difference between group RN and group RK (RR, 0.81 [98.3% CI −20.5 to 15.0]; P = 0.72). Although group R also showed a higher RR compared with group RN (RR = 1.79) and group RK (RR = 2.33) for patients using additional morphine within the second day after surgery, there was no significant difference in group comparisons by post hoc analysis (Table 3).

In all key secondary outcomes of adjusted analysis, the findings remained robust and results failed to demonstrate any significant differences between nalbuphine infiltration and ketorolac infiltration (see Table S2 in the electronic supplementary material for details).

Other Secondary Outcomes

By NRS measurements, there were no apparent differences in pain between the three groups at 2, 24, 48, and 72 h post-operation on resting state. However, NRS pain scores were significantly lower in group RN and group RK than in group R from 4 to 12 h after arrival at the ward (P < 0.001 for all time points) (see Fig. 3a and Table S3 in the electronic supplementary). Group R had higher pain scores than group RN and group RK at 4, 8, 12 and 24 h when taking a deep breath compared with the resting state pain scores. There were no significant differences in pain between group RN and group RK under either resting or moving conditions at any of the postoperative intervals (P = 1.00) (see Fig. 3b and Table S4 in the electronic supplementary).

Fig. 3.

NRS pain scores at 2, 4, 8, 12, 24, 48 and 72 h postoperatively after surgery in the three groups; a at rest; b on moving (taking a deep breath). NRS numerical rating scale, R ropivacaine, RN ropivacaine + nalbuphine, RK ropivacaine + ketorolac. Top and bottom of boxes indicate standard deviation; center lines indicate means. Tukey error bars are shown, which extend to the farthest points that are not outliers. Outliers (black circles) were defined as values greater than 1.5 times the standard deviation

Exploratory Outcomes

The proportions of patients with one or more adverse events in group R were 14.6% (95% CI 5.6–29.2), 14.3% (95% CI 5.4–28.5) in group RN and 12.2% (95% CI 4.1–26.2) in group RK. Adverse events did not differ significantly in any pairwise comparison (all P values > 0.05) (Table 4).

Table 4.

Exploratory outcomes

	Group R	Group RN	Group RK	P value
Total adverse events in 48 h post-surgery (95% CI) (%)	14.6 (5.6–29.2)	14.3 (5.4–28.5)	12.2 (4.1–26.2)	0.942a
Types of Adverse Events, (95% CI) (%)
Nausea	4.9 (0.6–16.5)	4.8 (0.6–16.2)	2.4 (0.1–12.9)	0.818b
Vomiting	4.9 (0.6–16.5)	2.4 (0.1–12.6)	2.4 (0.1–12.9)	0.765b
Local anesthetic toxicity	0	0	0	–
Hypotension	2.4 (0.1–12.9)	4.8 (0.6–16.2)	4.9 (0.6–16.5)	0.818b
Bradycardia	2.4 (0.1–12.9)	2.4 (0.1–12.6)	2.4 (0.1–12.9)	1.0b
Gastrointestinal bleeding	0	0	0	–
Pruritus	0	0	0	–
Wound infection	0	0	0	–

CI confidence interval, R ropivacaine, RN ropivacaine + nalbuphine, RK ropivacaine + ketorolac

^aChi-square test

^bFisher's exact test

Discussion

In this study, we explored the potential benefit of nalbuphine and ketorolac as an adjuvant for LWI in prolonging postoperative analgesia and relieving acute pain compared with ropivacaine alone. We hypothesized that nalbuphine and ketorolac as ropivacaine adjuvant could result in a longer duration of analgesia than ropivacaine alone and that ketorolac would be more effective in reducing acute postoperative pain than nalbuphine, but the results did not fully confirm these hypotheses. Both nalbuphine and ketorolac infiltration prolonged the duration of analgesia and reduced the additional rescue analgesia rates and the postoperative consumption of morphine. As reported for other peripheral nerve blocks, our results show that nalbuphine and ketorolac infiltration have a postoperative opioid-sparing effect [10, 16]. In addition, postoperative NRS pain scores within 12 h were lower in both the nalbuphine and the ketorolac infiltration groups compared with the ropivacaine alone group. The clinical relevance of these differences is likely high, as pain scores throughout the study period suggested adequate analgesia in both groups, with statistical significance. The adverse events were low in the three groups, with no significant differences.

The relatively restricted duration of local anesthetics used on their own is a major limitation of LWI. In addition, there remain clinical gaps in the use of different types of adjuncts to enhance the effectiveness of LWI [3, 7]. Nalbuphine, a mixed agonist–antagonist opioid, was found to prolong the duration of analgesia in supraclavicular brachial block, subarachnoid block and epidural block as an adjuvant to local anesthetics. To the best of our knowledge, this aspect of nalbuphine infiltration has not been previously investigated [9–11], and Johnny-Wei et al. reported a systematic review showing 35 randomized controlled trials examining opioid wound infiltration, which is the most well-studied class [3].

Although some studies have shown the existence of opioid receptors in the peripheral neurons, the peripheral mechanisms of opioid wound infiltration are unclear. We preliminarily determined that surgery and the ensuing inflammation could lead to the upregulation of opioid receptors at peripheral nerve endings and enhanced sensitivity of the opioids at these sites [21, 22]. Locally infiltrated opioids act on opioid receptors in peripheral tissues and nerves, while producing anti-inflammatory effects by reducing substance P and norepinephrine [23]. In addition to their opioid effects, another possible analgesic mechanism is the blocking of nerve conduction through a voltage-gated sodium channel [24, 25]. Of course, the altered pH of local anesthetic solutions resulting from the addition of adjuvants can also prolong analgesic duration [11].

The exact mechanism of local corticosteroid is also poorly understood. The possible analgesia mechanisms of NSAID infiltration include inhibition of peripheral prostaglandin synthesis, a decrease in inflammatory mediators, suppression of neuronal discharge, and reduction in transmission in nociceptive C fibers [26]. Bai et al. reported that there exists strong evidence that ketorolac 30–60 mg co-infiltration with local anesthetic reduces opioid requirements, prolongs analgesia duration, and reduces pain scores [3]. They also recommended further high-quality studies, though ketorolac showed great potential as an infiltration adjunct.

In terms of dose selection of the two adjuvants, ketorolac 30–60 mg appears to be an effective infiltration agent, with peripheral analgesia beyond the effects of general systemic absorption [3]. In previous studies, the analgesic effect of 10 mg nalbuphine was better than 5 mg, with reduced side effects [27]. We therefore used 10 mg nalbuphine in this study. Ketorolac dose was calculated based on that of nalbuphine (10 mg nalbuphine i.v. = 10 mg morphine i.v. = 25 mg ketorolac i.v.), and was slightly lower than 30 mg (a minimum dose of peripheral analgesia beyond the effects of systemic absorption) [19]. It is not difficult to explain why our results deviate from our assumptions—in other words, there might be a significant difference between ketorolac and nalbuphine infiltration groups if the dose of ketorolac infiltration dose were increased.

While both ketorolac and nalbuphine infiltration reduced opioid use in this study, their roles in reducing postoperative nausea and vomiting after open colorectal surgery yielded contradictory results. Normally, reducing opioid consumption is closely related to a decrease in nausea and vomiting [9]. However, the small sample size of our study and among-individuals differences may partially explain this phenomenon. Therefore, further studies in a larger sample size are needed to truly elucidate the effect of adjuvants infiltration on aspects of nausea and vomiting.

This study has several limitations. First, although powered to detect a difference in duration of analgesia between ketorolac and nalbuphine infiltration compared with ropivacaine alone, the sample size was relatively small. Second, we did not encounter any potential LWI-related adverse events, due to a lack of enough power to detect differences in adverse events in our study. LWI, however, was not associated with any risk of wound infection. Third, our multimodal analgesic protocol consisted of sufentanil administration via PCIA. We recognize that sufentanil could enhance the analgesic effect of nalbuphine infiltration through synergy, thereby weakening the analgesic effect of ketorolac infiltration [28, 29]. This could have affected the comparison of outcomes between nalbuphine and ketorolac infiltration. Fourth, this study lacks the combination of two adjuvants used (produce precipitation) and intravenous control; therefore, we cannot verify the specific pathway (via systemic absorption or through perineural action) and demonstrate that opioids plus NSAIDs as a co-adjuvant for LWI yield better analgesic effects. Fifth, the dose dependency and optimal dose were not determined in this study. Further research should investigate the optimal dose–effect relationship of adjuvant infiltration. Finally, the limited sample size from a single center and restrictive inclusion limit the generalization of the study. In addition, the findings may not be generalized to other institutions or other surgery types. The results should therefore be validated in a larger multicenter trial.

Conclusions

In conclusion, among patients undergoing open colorectal surgery, nalbuphine and ketorolac infiltration significantly prolonged analgesia duration and reduced morphine consumption compared with ropivacaine alone after surgery. Generally, the infiltration of these agents appears to be safe, but the results should be interpreted with caution as exploratory outcomes. However, ketorolac infiltration did not result in a clinically important improvement over nalbuphine infiltration, indicating that an equivalent analgesic dose of nalbuphine and ketorolac as local anesthetic adjuvants in LWI may have a similar analgesic effect.

Supplementary Information

Below is the link to the electronic supplementary material.